MenaQ7 MK-7
MenaQ7 MK-7 is a vitamin K2 supplement, specifically the MK-7 variant, which plays a crucial role in blood clotting and bone health. It is a form of menaquinone, a type of vitamin K.
Effectiveness and Risk Overview
Condition | Effectiveness | Details |
|---|---|---|
| Osteoporosis | MenaQ7 MK-7's role in bone health is well-documented. It helps in the carboxylation of osteocalcin, which is essential for bone mineralization. This action is associated with improved bone density and reduced risk of osteoporotic fractures. | |
| Cardiovascular Health | By reducing arterial calcification and improving blood vessel elasticity, MenaQ7 MK-7 contributes to overall cardiovascular health. Its effects on MGP activation are crucial for preventing the calcification of arteries, thereby reducing cardiovascular risk. | |
| Bone Health | MenaQ7 MK-7 is involved in the activation of osteocalcin, a protein necessary for bone mineralization. Studies have demonstrated its role in improving bone mineral density and reducing the risk of fractures, particularly in postmenopausal women. | |
| Vascular Calcification | MenaQ7 MK-7 has been shown to reduce vascular calcification by activating MGP. This is critical for maintaining vascular health and preventing cardiovascular diseases associated with calcification. | |
| Arterial Calcification/Atherosclerosis | MenaQ7 MK-7 has been shown to inhibit arterial calcification and reduce the risk of cardiovascular disease by activating matrix Gla protein (MGP), a potent inhibitor of arterial calcification. Clinical trials and meta-analyses support its efficacy in reducing arterial stiffness and calcification. | |
| Potential interaction with anticoagulants. | MenaQ7 MK-7 may interact with anticoagulant medications like warfarin, potentially altering their efficacy or increasing the risk of bleeding. |
Recommended Supplement